Sherman L A, Harwig S, Lee J
J Lab Clin Med. 1975 Jul;86(1):100-11.
Fbrinogen:fibrin complexes have been previously described in various thrombotic disorders. To evaluate further the properties of fibrinogen:fibrin complexes, and theirin vitro and in vivo behavior, soluable fibrinogen:fibrin complexes have been formed invitro using mixtures of '131l-fibrinogen ('131l-F) and '125l-fibrin ('125l-fb). By means of Sepharose 4B chromatography, a macromolecular complex (peak one) containing both moieties could be separated from a lower molecular weight peak two containg noncomplexed material. The latter eluted at the same position as did intact fibrogen. Both the '131l-F and '125l-fb components of peak one were rapidly catabolized when injected into rabbits with residual blood activity at 24 hours of 8 per cent and 4 per cent, respectively. Peak two behavedas a simple mixture with corresponding 24-hour levels at 31 per cent and 3 per cent. Gel filtration of postinjuection plasma samples demonstrated that peak one remained as macromolecular complex. Preinjection crosslinking of the F:fb complex with factor xiii did not substantially change the blood clearance. Prior blockage of the reticuloendotheial system with Thorotrast or carbon resulted in impaired clearance of peak one. The data provide evidence that fibrinogen and fibrin can form a macromolecular complex which is stable both in vitro and vivo. Further, the reticuloendotheialsystem was shown to mediate the the in vivo clearance of this complex. This latterfinding may be of pathophysiologic significance.
纤维蛋白复合物先前已在各种血栓性疾病中被描述。为了进一步评估纤维蛋白原:纤维蛋白复合物的特性及其体外和体内行为,已使用¹³¹I - 纤维蛋白原(¹³¹I - F)和¹²⁵I - 纤维蛋白(¹²⁵I - fb)的混合物在体外形成可溶性纤维蛋白原:纤维蛋白复合物。通过琼脂糖4B色谱法,可以从含有未复合物质的较低分子量峰2中分离出包含两个部分的大分子复合物(峰1)。后者在与完整纤维蛋白原相同的位置洗脱。当将峰1的¹³¹I - F和¹²⁵I - fb成分注射到兔子体内时,它们都被迅速分解代谢,24小时时残留血液活性分别为8%和4%。峰2表现为简单混合物,相应的24小时水平分别为31%和3%。注射后血浆样品的凝胶过滤表明峰1保持为大分子复合物。注射前用因子XIII对F:fb复合物进行交联并没有实质性改变血液清除率。用钍胶体或碳预先阻断网状内皮系统会导致峰1的清除受损。数据提供了证据表明纤维蛋白原和纤维蛋白可以形成一种在体外和体内都稳定的大分子复合物。此外,网状内皮系统被证明介导了这种复合物的体内清除。后一发现可能具有病理生理学意义。